Old and new facts of probiotics: Where we are and where we are going

CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources

Volumn 3, Issue , 2008, Pages

  Mayo, Baltasar ^a   Delgado, Susana ^a   Rodríguez, Juan M ^b   Gueimonde, Miguel ^a  

^a DEPARTMENT OF MICROBIOLOGY AND BIOCHEMISTRY OF DAIRY PRODUCTS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Bifidobacterium; Functional dairy products; Functional foods; Lactobacillus; Probiosis; Probiotics

Indexed keywords

EID: 84872749110     PISSN: None     EISSN: 17498848     Source Type: Journal    
DOI: 10.1079/PAVSNNR20083055     Document Type: Review

References (173)

1. Fuller R. Probiotics in man and animals. Journal of Applied Bacteriology 1989;66:365-78.
2. FAO/WHO (Food and Health Agricultural Organization of the United Nations and World Health Organization). Guidelines for the evaluation of probiotics in food. Working Group Report. FAO/WHO, London, Ontario, Canada; 2002.
3. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126:1358-73.
4. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signalling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-8.
5. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;360:512-9.
6. Klaenhammer TR, Kullen MJ. Selection and design of probiotics. International Journal of Food Microbiology 1999;45:45-57.
7. Ouwehand AC. Probiotics: time to move beyond Metchnikoff? Drug Discovery Today 2003;8:1063.
8. Salminen S, Lahtinen S, Gueimonde M. Probiotics and the reduction in risk of disease. Australian Journal of Dairy Technology 2005;60:99-103.
9. Dunne C, Murph L, Flynn S, O'Mahony L, O'Halloran S, Feeney M, et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie van Leeuwenhoek 1999;76:279-92.
10. Dunne C, O'Mahony L, Murphy L, Thornton G, Morrisey D, O'Halloran S, et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. The American Journal Clinical Nutrition 2001;73 Suppl. 2:386-92.
11. Ouwehand AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. Antonie van Leeuwenhoek 2002;82:279-89.
12. Holzapfel WH, Haberer P, Geisen R, Björkroth J, Schillinger U. Taxonomy and important features of probiotic microorganisms in food and nutrition. The American Journal Clinical Nutrition 2001;73 Suppl. 2:365-73.
13. Mattila-Sandholm T, Myllärinen P, Crittenden R, Mogensen G, Fondén R, Saarela M. Technological challenges for future probiotic foods. International Dairy Journal 2002;12:173-82.
14. Gasser F. Safety of lactic acid bacteria and their occurrence in human clinical infections. Bulletin of the Institute Pasteur 1994;92:45-67.
15. Parodi PW. The role of intestinal bacteria in the causation and prevention of cancer: modulation by diet and probiotics. Australian Journal of Dairy Technology 1999;54:103-21.
16. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotics resistance genes. Trends in Microbiology 2004;12:412-6.
17. Gueimonde M, Salminen S. New methods for selecting and evaluating probiotics. Digestive and Liver Disease 2006;38 Suppl. 2:242-7.
18. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clinical Infectious Diseases 2004;38:62-9.
19. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.
20. Muñoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Pérez MJ, Sánchez-Somolinos M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clinical Infectious Diseases 2005;40:1625-34.
21. Ouwehand AC, Bianchi Salvadori B, Fondén R, Mogensen G, Salminen S, Sellars R. Health effects of Probiotics and culture-containing dairy products in humans. Bulletin of the IDF 2003;380:4-19.
22. Pelletier X, Laure-Boussuge S, Donazzolo Y. Hydrogen excretion upon ingestion of dairy products in lactoseintolerant male subjects: importance of the live flora. European Journal of Clinical Nutrition 2001;55:509-12.
23. de Vrese M, Stegelmann A, Richter B, Fenselau S, Laue C, Schrezenmeir J. Probiotics: compensation for lactase insufficiency. The American Journal of Clinical Nutrition 2001;73 Suppl. 2:421-9.
24. Koo HL, DuPont HL. Current and future developments in travelers' diarrhea therapy. Expert Review of Anti-infective Therapy 2006;4:417-27.
25. Paton AW, Jennings MP, Morona R, Wang H, Focareta A, Roddam LF, et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 2005;128:1219-28.
26. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea, Emerging Infectious Diseases 2006;12:304-6.
27. Colbère-Garapin F, Martin-Latil S, Blondel B, Mousson L, Pelletier I, Autret A, et al. Prevention and treatment of enteric viral infections: possible benefits of probiotic bacteria. Microbes and Infection 2007;9:1623-31.
28. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. Journal of Pediatrics 2001;138:361-5.
29. van Niel CW, Feudtner C, Garrison MM, Christakis DA. Lactobacillus therapy for acute infectious diarrhoea in children: a meta-analysis. Pediatrics 2002;109:678-84.
30. Guandalini S, Pensabene L, Zikri MA, Dias J, Casali LG, Hoekstra H, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. Journal of Pediatric Gastroenterology and Nutrition 2000;30:54-60.
31. Thomson I. Clostridium difficile-associated disease: update and focus on non-antibiotic strategies. Age and Ageing 2008;37:14-8.
32. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial. Alimentary Pharmacology and Therapeutics 2005;21: 583-90.
33. Can M, Besirbellioglu BA, Avci IY, Bekker CM, Pahsa A. Prophylactic Saccharomyces boulardii in the prevention of antibiotic associated diarrhea: a prospective study. Medical Science Monitor 2006;12:19-22.
34. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. American Journal of Gastroenterology 2006;101:812-22.
35. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea. A meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infectious Disease 2006;6:374-82.
36. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-bialek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Alimentary Pharmacology and Therapeutics 2007;25:871-81.
37. Szajewska H, Skorka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Alimentary Pharmacology and Therapeutics 2007;25:257-64.
38. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scandinavian Journal of Infectious Disease 2003;35:365-7.
39. McFarland LV. Meta-analysis of probiotics for the prevention of traveller's diarrhea. Travel Medicine and Infectious Disease 2007;5:97-105.
40. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006;55:205-11.
41. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-33.
42. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.
43. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
44. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9.
45. Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55:842-7.
46. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
47. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. European Journal of Gastroenterology and Hepatology 2003;15:697-8.
48. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54:242-9.
49. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Digestive Diseases and Sciences 2008;53:1278-84.
50. Lacy BE, Lee RD. Irritable bowel syndrome: a syndrome in evolution. Journal of Clinical Gastroenterology 2005;39 Suppl. 3:230-42.
51. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal inmune system in irritable bowel syndrome. Gastroenterology 2002;122: 1778-83.
52. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. The American Journal of Gastroenterology 2000;95:1231-8.
53. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacteria overgrowth reduces symptoms of irritable bowel syndrome. The American Journal of Gastroenterology 2000;95:3503-6.
54. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.
55. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35 624 in women with irritable bowel syndrome. The American Journal of Gastroenterology 2006;107:1581-90.
56. Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by he human Lactobacillus acidophilus strain LB. Applied Environmental Microbiology 1998;64:4573-80.
57. Aiba Y, Suzuki N, Kabir AM, Takagi A, Koga Y. Lactic acid mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. The American Journal of Gastroenterology 1998;93:2097-101.
58. Wang KY, Li SN, Liu CS, Perng DS, Su YC, Wu DC, et al. Effects of ingesting Lactobacillus-and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. The American Journal of Clinical Nutrition 2004;80:737-41.
59. Sheu BS, Cheng HC, Kao AW, Wang ST, Yang YJ, Yang HB, et al. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. The American Journal of Clinical Nutrition 2006;83:864-9.
60. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. The American Journal of Gastroenterology 2002;97:2744-9.
61. Salminen S, Ouwehand AC, Isolauri E. Clinical applications of probiotic bacteria. International Dairy Journal 1998; 8:563-72.
62. Bin-Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. Journal of Pediatrics 2005;147:192-6.
63. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005;115:1-4.
64. Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biology of the Neonate 2002;82:103-8.
65. Alfaleh K, Bassler D. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews 2008;23:CD005496.
66. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet 2007;369:1614-20.
67. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003;361:1496-501.
68. Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics, a role in chemoprevention for colorectal cancer? Cancer Biology and Therapy 2006;5:1265-9.
69. Rowland I. Probiotics and colorectal cancer risk. The British Journal of Nutrition 2004;91:805-7.
70. Ohashi Y, Nakai S, Tsukamoto T, Masumori N, Akaza H, Miyanaga N, et al. Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urology International 2002;68:273-80.
71. Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. American Journal of Clinical Nutrition 2007;85:488-96.
72. El-Nezami H, Polychronaki N, Salminen S, Mykkanen H. Binding rather than metabolism may explain the interaction of two food-grade Lactobacillus strains with zearalenone and its derivative a-earalenol. Applied and Environmental Microbiology 2002;68:3545-9.
73. Meriluoto J, Gueimonde M, Haskard CA, Spoof L, Sjövall O, Salminen S. Removal of the cyanobacterial toxin microcystin-LR by human probiotics. Toxicon 2005;46:111-4.
74. Halttunen T, Salminen S, Tahvonen R. Rapid removal of lead and cadmium from water by specific lactic acid bacteria. International Journal of Food Microbiology 2007;114:30-5.
75. Reid G, Kim SO, Köhler GA. Selecting, testing and understanding probiotic microorganisms. FEMS Immunology and Medical Microbiology 2006;46:149-57.
76. Sleator RD, Hill C. New frontiers in probiotic research. Letters in Applied Microbiology 2008;46:143-7.
77. Ouwehand AC. Antiallergic effects of probiotics. The Journal of Nutrition 2007;137 Suppl. 2:794-7.
78. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clinical and Experimental Allergy 2000;30:1605-10.
79. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial. Lancet 2001;357:1076-9.
80. Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial. Lancet 2003;361:1869-71.
81. Lee J, Seto D, Bieloty L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. Journal of Allergy and Clinical Immunology 2008;121:116-21.
82. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunology and Medical Microbiology 2003;35:131-4.
83. Othman M, Neilson JP, Alfirevic Z. Probiotics for preventing preterm labour. Cochrane Database of Systematic Reviews 2007;24:CD005941.
84. Hammerman C, Kaplan M. Probiotics and neonatal intestinal infection. Current Opinion in Infectious Diseases 2006;19:277-82.
85. Lucas A, Cole TJ. Breast milk and neonatal necrotising enterocolitis. Lancet 1990;336:1519-23.
86. Ronnestad A, Abrahamsen TG, Melbø S, Reigstad H, Lossius K, Kaaresen PI, et al. Septicemia in the first week of life in a Norwegian national cohort of extremely premature infants. Pediatrics 2005;115:262-8.
87. Schanler RJ. Overview: the clinical perspective. Journal of Nutrition 2000;130:417S-9S.
88. Hatakka K, Savilahti E, Pönkä A, Meurman JH, Poussa T, Näse L, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. British Medical Journal 2001;322:1-5.
89. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005;115:5-9.
90. Meurman JH. Probiotics: do they have a role in oral medicine and dentistry? European Journal of Oral Science 2005;113:188-96.
91. Näse L, Hatakka K, Savilahti E, Saxelin M, Pönkä A, Poussa T, et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Research 2001;35:412-20.
92. Ahola AJ, Yli-Knuuttila H, Suomalainen T, Poussa T, Ahlstrom A, Meurman JH, et al. Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. Archives of Oral Biology 2002;47:799-804.
93. Hatakka K, Ahola A, Yli-Knuuttila H, Richardson M, Poussa T, Suomalainen T, et al. Probiotics reduce the prevalence of oral candida in the elderly - a randomized controlled trial. Journal of Dental Research 2007;86:125-30.
94. Henriksson R, Franzen L, Sandström K, Nordin A, Arevarn M, Grahn E. The effects of active addition of bacterial cultures in fermented milk to patients with chronic bowel discomfort following irradiation. Support Care Cancer 1995;3:81-3.
95. Salminen E, Salminen S, Vapaatalo H, Holsti LR. Adverse effects of pelvic radiotherapy. In: Kogelnik HD, editor. International Meeting on Progress in Radio-oncology, 1995, Monduzzi Editore, Italy; 1995. p. 501-4.
96. Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006;312:1355-9.
97. Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. Current Opinion in Clinical Nutrition and Metabolic Care 2007;10:729-34.
98. Meier C, Plevy S. Therapy insight: how the gut talks to the joints. Nature Clinical Practice Rheumatology 2007;3: 667-74.
99. Generini S, Fiori G, Matucci Cerinic M. Therapy of spondylarthropathy in inflammatory bowel disease. Clinical and Experimental Rheumatology 2002;20:S88-94.
100. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proceedings of the National Academy of Sciences of the United States of America 2005;102:11070-5.
101. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-3.
102. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31.
103. Brugman S, Klatter FA, Visser JT, Wildeboer-Veloo AC, Harmsen HJ, Rozing J, et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes?. Diabetologia 2006;49:2105-8.
104. Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML, Bolte E, et al. Gastrointestinal microflora studies in late-onset autism. Clinical Infectious Diseases. 2002;35 Suppl. 1:6-16.
105. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Applied and Environmental Microbiology 2004;70:6459-65.
106. Parracho HM, Bingham MO, Gibson GR, McCartney AL. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. Journal of Medical microbiology 2005;54:987-91.
107. Hobson AR, Aziz Q. Modulation of visceral nociceptive pathways. Current Opinion in Pharmacology 2007;7:593-7.
108. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine 2007;13:35-7.
109. Guéniche A, Benyacoub J, Buetler TM, Smola H, Blum S. Supplementation with oral probiotic bacteria maintains cutaneous immune homeostasis after UV exposure. European Journal of Dermatology 2006;16:511-7.
110. Torii A, Torii S, Fujiwara S, Tanaka H, Inagaki N, Nagai H. Lactobacillus acidophilus strain L-92 regulates the production of Th1 cytokine as well as Th2 cytokines. Allergology International 2007;56:293-301.
111. Diano S, Farr SA, Benoit SC, McNay EC, da Silva I, Horvath B, et al. Ghrelin controls hippocampal spine synapse density and memoty performance. Nature Neurosciences 2006;9:381-8.
112. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. Journal of Physiology 2004;558:263-75.
113. Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific Lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. The British Journal of Surgery 2002;89:1103-7.
114. van Minnen LP, Timmerman HM, Lutgendorff F, Verheem A, Harmsen W, Konstantinov SR, et al. Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. Surgery 2007;141:470-80.
115. Besselink MG, Timmerman HM, Buskens E, Nieuwenhuijs VB, Akkermans LM, Gooszen HG. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial. BMC Surgery 2004;29:4-12.
116. Besselink MGH, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. The Lancet 2008;371:651-9.
117. Lankaputhra WEV, Shah NP. Survival of Lactobacillus acidophilus and Bifidobacterium spp. in the presence of acid and bile salts. Cultured Dairy Products Journal 1995;30:2-7.
118. Charteris WP, Kelly PM, Morelli L, Collins JK. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. Journal of Applied Microbiology 1998;84:759-68.
119. Shah NP. Probiotic bacteria: enumeration and survival in dairy foods. Journal of Dairy Science 2000;83:894-907.
120. Maus JE, Ingham SC. Employment of stressful conditions during culture production to enhance subsequent cold- and acid-tolerance of bifidobacteria. Journal of Applied Microbiology 2003;95:146-54.
121. Saarela M, Rantala M, Hallamaa K, Nohynek L, Virkajarvi I, Matto J. Stationary-phase acid and heat-treatments for improvement of the viability of probiotic lactobacilli and bifidobacteria. Journal of Applied Microbiology 2004;96:1205-14.
122. Anastasiou R, Leverrier P, Krestas I, Rouault A, Kalantzopoulos G, Boyaval P, et al. Changes in protein synthesis during thermal adaptation of Propionibacterium freudenreichii subsp. shermanii. International Journal of Food Microbiology 2006;108:301-14.
123. Corcoran BM, Ross RP, Fitzgerald GF, Dockery P, Stanton C. Enhanced survival of GroESL-overproducing Lactobacillus paracasei NFBC338 under stressful conditions induced by drying. Applied and Environmental Microbiology 2006;72:5104-7.
124. Sánchez B, Champomier-Vergés MC, Anglade P, Baraige F, de los Reyes-Gavilán CG, Margolles A, et al. Proteomic analysis of global changes in protein expression during bile salt exposure of Bifidobacterium longum NCIMB 8809. Journal of Bacteriology 2005;187:5799-808.
125. Sánchez B, Champomier-Vergès MC, Collado MC, Anglade P, Baraige F, Sanz Y, et al. Low-pH adaptation and the acid tolerant response of Bifidobacterium longum biotype longum. Applied and Environmental Microbiology 2007;73:6450-9.
126. De Dea Lindner J, Canchaya C, Zhang Z, Neviani E, Fitzgerald GF, van Sinderen D, et al. Exploiting Bifidobacterium genomes: the molecular basis of stress response. International Journal of Food Microbiology 2007;120:13-24.
127. Noriega L, Gueimonde M, Sánchez B, Margolles A, de los Reyes-Gavilán CG. Effect of the adaptation to high bile salts concentrations on glycosidic activity, survival at low pH and cross-resistance to bile salts in Bifidobacterium. International Journal of Food Microbiology 2004;94:79-86.
128. Gueimonde M, Noriega L, Margolles A, de los Reyes-Gavilan CG, Salminen S. Ability of Bifidobacterium strains with acquired resistance to bile to adhere to human intestinal mucus. International Journal of Food Microbiology 2005;101:341-6.
129. Gueimonde M, Margolles A, de los Reyes-Gavilan CG, Salminen S. Competitive exclusion of enteropathogens from human intestinal mucus by Bifidobacterium strains with acquired resistance to bile - a preliminary study. International Journal of Food Microbiology 2007;113:228-32.
130. Collado MC, Gueimonde M, Sanz Y, Salminen S. Adhesion properties and competitive pathogen exclusion ability of bifidobacteria with acquired acid resistance. Journal of Food Protection 2006;69:1675-9.
131. Sheehan VM, Sleator RD, Fitzgerald GF, Hill C. Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Applied and Environmental Microbiology 2006;72:2170-7.
132. Sheehan VM, Sleator RD, Hill C, Fitzgerald GF. Improving gastric transit, gastrointestinal persistence and therapeutic efficacy on the probiotic strain Bifidobacterium breve UCC2003. Microbiology 2007;153:3563-71.
133. Termont S, Vanderbroucke K, Iserentant D, Nirynck S, Steidler L, Remaut E, et al. Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance. Applied and Environmental Microbiology 2006;72:7694-700.
134. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nature Biotechnology 2003;21:785-9.
135. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-5.
136. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clinical Gastroenterology and Hepatology 2006;4:754-9.
137. Bermúdez-Humarán LG, Langella P, Cortes-Perez NG, Gruss A, Tamez-Guerra RS, Oliveira SC, et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infection and Immunity 2003;71:1887-96.
138. Bermúdez-Humarán LG, Cortes-Perez NG, L'haridon R, Langella P. Production of biological active murine IFN-gamma by recombinant Lactococcus lactis. FEMS Microbiology Letters 2008;280:144-9.
139. Bermúdez-Humarán LG, Nouaille S, Zilberfarb V, Corthier G, Gruss A, Langella P, et al. Effects of intranasal administration of a leptin-secreting Lactococcus lactis recombinant on food intake, body weight, and immune response of mice. Applied and Environmental Microbiology 2007;73:5300-7.
140. Adel-Patient K, Ah-Leung S, Creminon C, Nouaille S, Chatel JM, Langella P, et al. Oral administration of recombinant Lactococcus lactis expressing bovine b-lactoglobulin partially prevents mice from sensitization. Clinical and Experimental Allergy 2005;35:539-46.
141. Vandenbroucke K, Hans W, Van Huysse J, Neirynk S, Demetter P, Renault E, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004;127:502-13.
142. Fujimori M, Nakamura T, Sasaki T, Yazawa K, Amano J, Kano Y, et al. Bifidobacterium longum as a gene delivery system for cancer gene therapy. Gene Therapy and Molecular Biology 2001;6:195-200.
143. Fujimori M. Genetically engineered Bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients. Breast Cancer 2006;13:27-31.
144. Focareta A, Paton JC, Morona R, Cook J, Paton AW. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 2006;130:1688-95.
145. Fernández L, Marín ML, Langa S, Martín R, Reviriego C, Fernández A, et al. A novel genetic label for detection of specific probiotic lactic acid bacteria. Food Science and Technology International 2004;10:101-8.
146. Buddenborg C, Daudel D, Liebrecht S, Greune L, Humberg V, Schmidt MA. Development of a tripartite vector system for live oral immunization using a Gram-negative probiotic carrier. International Journal of Medical Microbiology 2008;298:105-14.
147. Chang TLY, Chang CH, Simpson DA, Xu Q, Martin PK, Lagenaur LA, et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proceedings of the National Academy of Sciences of the United States of America 2003;100:11672-7.
148. Martín R, Langa S, Reviriego C, Jiménez E, Marín ML, Olivares O, et al. The commensal microflora of human milk: new perspectives for food bacteriotherapy and probiotics. Trends in Food Science and Technology 2004;15:121-7.
149. Perez PF, Doré J, Leclerc M, Levenez F, Benyacoub J, Serrant P, et al. Bacterial imprinting of the neonatal immune system: lessons from maternal cells? Pediatrics 2007;119:e724-32.
150. Rescigno M, Urbano M, Valsazina B, Francoloni M, Rotta G, Bonasio R, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nature Immunology 2001;2:361-7.
151. Bertotto A, Gerli R, Castellucci G, Scalise F, Vaccaro R. Human milk lymphocytes bearing the gamma/delta T-cell receptor are mostly delta TCS1-positive cells. Immunology 1991;74:360-1.
152. Jiménez E, Fernández L, Marín ML, Martín R, Odriozola JM, Nueno-Palop C, et al. Isolation of commensal bacteria from umbilical chord blood of healthy neonates born by caesarean section. Current Microbiology 2005;51:270-4.
153. Favier CF, Vaughan EE, de Vos WM, Akkermans ADL. Molecular monitoring of succession of bacterial communities in human neonates. Applied Environmental Microbiology 2002;68:219-26.
154. Martín R, Heilig HG, Zoetendal EG, Jimenez E, Fernandez L, Smidt H, et al. Cultivation-independent assessment of the bacterial diversity of breast milk among healthy women. Research in Microbiology 2007;158:31-7.
155. Martín R, Heilig HGHJ, Zoetendal EG, Smidt H, Rodríguez JM. Diversity of the Lactobacillus group in breast milk and vagina of healthy women and potential role in the colonization of the infant gut. Journal of Applied Microbiology 2007;103;6:2638-44.
156. Gdalevich M, Mimouni D, Mimouni M. Breast-feeding and the risk of bronchial asthma in childhood: a systematic review with meta-analysis of prospective studies. Journal of Pediatrics 2001;139:261-6.
157. Gdalevich M, Mimouni D, David M, Mimouni M. Breastfeeding and the onset of atopic dermatitis in childhood: a systematic review with meta-analysis of prospective studies. Journal of the American Academy of Dermatology 2001;45:520-7.
158. Kalliomäki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. Journal of Allergy and Clinical Immunology 2001;107:129-34.
159. Heikkilä MP, Saris PEJ. Inhibition of Staphylococcus aureus by the commensal bacteria of human milk. Journal of Applied Microbiology 2003;95:471-8.
160. Martín R, Olivares M, Marín ML, Fernández L, Xaus J, Rodríguez JM. Probiotic potential of 3 lactobacilli strains isolated from breast milk. Journal of Human Lactation 2005;21:8-17.
161. 2 produced by viridans group streptococci may contribute to inhibition of methicillin-resistant Staphylococcus aureus colonization of oral cavities in newborns. Clinical Infectious Diseases 2001;32:1408-13.
162. Kirjavainen PV, Apostolou E, Arvola T, Salminen SJ, Gibson GR, Isolauri E. Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunology and Medical Microbiology 2001;32:1-7.
163. Lodínová -Žádníková R, Sonnenborn U. Effect of preventive administration of a non-pathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biology of the Neonate 1997;71:224-32.
164. Cukrowska B, Lodínová - Žádníková R, Enders C, Sonnenborn U, Schulze J, Tlaskalova-Hogenova H. Specific proliferative and antibody responses of premature infants to intestinal colonization with non-pathogenic probiotic E. coli strain Nissle 1917. Scandinavian Journal of Immunology 2002;55:204-9.
165. Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS. Oxalobacter formigenes and its potential role in human health. Applied and Environmental Microbiology 2002;68:3841-7.
166. Stewart CS, Duncan SH, Cave DR. Oxalobacter formigenes and its role in oxalate metabolism in the human gut. FEMS Microbiology Letters 2004;230:1-7.
167. Duncan SH, Hold GL, Barcenilla A, Stewart CS, Flint HJ. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. International Journal of Systematic and Evolutionary Microbiology 2002;52:1615-20.
168. Duncan SH, Louis P, Flint HJ. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Applied and Environmental Microbiology 2004;70:5810-7.
169. Gérard P, Lepercq P, Leclerc M, Gavini F, Raibaud P, Juste C. Bacteroides sp. strain D8, the first cholesterol-reducing bacterium isolated from human feces. Applied and Environmental Microbiology 2007;73:5742-9.
170. Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ. Bacterial biota in the human distal esophagus. Proceeding of the National Academy of Science of the United States of America 2004;101:4250-5.
171. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proceedings of the National Academy of Sciences of the United States of America 2006;103:732-7.
172. Walter J, Schwab C, Loach DM, Gänzle MG, Tannock GW. Glucosyltransferase A (GtfA) and inulosucrase (Inu) of Lactobacillus reuteri TMW1.106 contribute to cell aggregation, in vitro biofilm formation, and colonization of the mouse gastrointestinal tract. Microbiology 2008;154:72-80.
173. EC Regulation no.1924/2006. Regulation of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. Official Journal of the European Union, L 404 of 30 December 2006.